PATENT CLAIM ANALYSIS

Application Number: 15926407
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "170000"]

Abstract:
A method for contraception includes administering to a female daily, during a time period of 21 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein the drug formulation is administered in a biphasic dosing regimen comprising a 14 day phase and a 7 day phase, wherein doses of each of the norethindrone acetate and EE in the second phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the norethindrone acetate and EE administered during the first phase of the regimen, wherein the norethindrone acetate dose in the first phase is 1000 mcg and in the second phase is 1500 mcg, wherein the EE dose in the first phase is 20 mcg and in the second phase is 30 mcg, and wherein the biphasic dosing regimen is followed by 7 days without norethindrone acetate and EE administration.

Claim (Index 10):
The method of  claim 9 , wherein the oral combination drug formulation is in a form of any one of: an oral tablet, an oral capsule, and an oral caplet.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 90.0
- Lexical Diversity: 2.46154
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14301768', '15593771', '08115008', '08462703', '12534902']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7989387909573215
- 35 USC 102 Novelty (BERT): 0.6907219349916037
- Combined Prediction Score: 0.7881171053607497
- Mean Citation Score: 505.94129600000014
- Max Citation Score: 698.2487
- Similarity Product: 685.3202571690023

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test